Nexentis Technologies Stock Price, News & Analysis
Company Description
Nexentis Technologies Inc. is a Nasdaq-listed operating company focused on biotechnology drug discovery and solar energy asset investments. The company describes itself as a drug discovery company that also invests in solar energy assets using a Ready to Build business model. Its common stock trades on the Nasdaq Capital Market under the symbol NXTS, and the company is incorporated in Nevada with corporate operations identified in Neve Yarak, Israel.
The company’s biotechnology activity is conducted through its wholly owned subsidiary, MitoCareX Bio Ltd. MitoCareX is focused on mitochondrial drug discovery, including therapeutic programs for inflammatory metabolic diseases and cancer that target specific metabolic pathways. Its proprietary algorithm platform, MITOLINE™, is a sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for 3D homology modeling. The platform is intended to address the lack of solved three-dimensional structures for many human mitochondrial carriers by aligning and annotating amino acid sequences and residues for comparative modeling.
Nexentis also reports an investment focus in solar energy assets based on the RTB model, which refers to projects that are ready to build. In addition, the company controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.
The company’s public-company record includes capital-structure actions and shareholder approvals. In April 2026, Nexentis effected a one-for-seven reverse stock split of its common stock, after which the shares continued trading on Nasdaq under the NXTS symbol with a new CUSIP number. Its proxy and current-report disclosures also cover stockholder voting matters, Nasdaq Marketplace Rule 5635(d) equity-issuance approvals, material agreements, and amendments affecting common-stock rights.
Stock Performance
Nexentis Technologies (NXTS) stock last traded at $5.08, down 6.37% from the previous close. Over the past 12 months, the stock has lost 29.5%. At a market capitalization of $3.9M, NXTS is classified as a micro-cap stock with approximately 1.0M shares outstanding.
NXTS Rankings
Latest News
Nexentis Technologies has 5 recent news articles, with the latest published yesterday. Of the recent coverage, 4 articles coincided with positive price movement and 1 with negative movement. Key topics include clinical trial, AI. View all NXTS news →
SEC Filings
Nexentis Technologies has filed 8 recent SEC filings, including 5 Form 8-K, 2 Form 10-Q, 1 Form 424B5. The most recent filing was submitted on June 15, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all NXTS SEC filings →
Financial Highlights
operating income reached -$4.2M, and net income was -$4.0M. Diluted earnings per share stood at $-8.61. The company generated -$3.8M in operating cash flow. With a current ratio of 4.19, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Nexentis Technologies (NXTS) currently stands at 25.1 thousand shares, up 10.2% from the previous reporting period, representing 3.5% of the shares outstanding. Over the past 12 months, short interest has decreased by 36.2%.
Days to Cover History
Days to cover for Nexentis Technologies (NXTS) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 1.7 days.
NXTS Company Profile & Sector Positioning
Nexentis Technologies (NXTS) operates in the Agricultural Inputs industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.